CMS finalizes Medicare coverage policy for Alzheimer’s drug 

Apr 08, 2022 - 02:31 PM
CMS_update

The Centers for Medicare & Medicaid Services yesterday to cover only for Medicare beneficiaries enrolled in qualifying clinical trials monoclonal antibodies that target amyloid to treat Alzheimer’s disease when approved by the Food and Drug Administration. The FDA last year approved the first such Alzheimer’s treatment, Biogen’s Aduhelm (aducanumab), using its accelerated approval pathway.

Related News Articles

Headline
CMS warns of phishing fax scheme; AHA monitoring other reported social engineering schemes 
The Centers for Medicare & Medicaid Services today announced it has identified a fraud scheme targeting Medicare providers and suppliers. CMS said scammers…
Headline
NORC, Coalition report finds MA patients face longer hospital stays, reduced follow-up care access 
A report released June 17 by NORC at the University of Chicago, commissioned by the Coalition to Strengthen America’s Healthcare, found that patients enrolled…
Headline
CMS requests comments on MA service level data collection for initial determinations, appeals
The Centers for Medicare and Medicaid Services May 30 released a notice requesting comments on a proposed Medicare Advantage service level data collection…
Headline
AHA comments to CMS on FY 2026 IPPS proposal
The AHA commented to the Centers for Medicare & Medicaid Services June 10 on the fiscal year 2026 inpatient prospective payment system proposed rule (https…
Headline
Reduced FY 2026 LTCH payment updates ‘inadequate,’ AHA tells CMS
The AHA expressed concerns (LINK) to the Centers for Medicare & Medicaid Services today on payment updates for the fiscal year 2026 proposed rule for the…
Headline
AHA provides comments on TEAM proposed rule, asks CMS to make voluntary
The AHA commented on proposed changes to the Transforming Episode Accountability Model, a new, mandatory, episode-based payment model scheduled to begin Jan. 1…